Phase 3 Readout~month

Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate

Indication
Negative Symptoms of Schizophrenia

Other upcoming events for NERV

Phase 3 ReadoutPhase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate — NERV Phase 3 Readout | BioSniper